Cutaneous T Cell Lymphomas News and Research

RSS

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.

17 Oct 2022

PD1 gene deletions associated with worse prognoses of cutaneous T-cell lymphomas

Immunohistochemistry staining showing PD1 expression on tumor cells in a skin biopsy from a cutaneous T-cell lymphoma patient.

5 Aug 2021

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

Under Australia's Pharmaceutical Benefits Scheme (PBS), soon many of the rare diseases and their treatments are set to become cheaper.

21 Mar 2019

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

26 Apr 2013

Research project to identify mechanisms underlying effects of cancer drug interferon-α

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells.

24 Apr 2013

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Dendritic cells tricked into action against cancer

A new type of immunotherapy in which dendritic cells are tricked into action against cancer when they are exposed to harmless pieces of viruses and bacteria is described in the November issue of Cancer Research.

1 Nov 2005

Genmab's HuMax-CD4 receives U.S. orphan drug designation

Genmab has announced that HuMax-CD4 for the treatment of Mycosis Fungoides (MF), which constitutes 75% of all Cutaneous T-cell Lymphomas (CTCL), has been designated an orphan drug by the US Food and Drug Administration (FDA). The US prevalence of MF is estimated at 16,000 to 20,000.

23 Aug 2004